⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27754498 | 1.00 | — | — | |
| SCHEMBL29732618 | 1.00 | — | — | |
| SCHEMBL29419920 | 1.00 | — | — | |
| SCHEMBL11140332 | 1.00 | CA1 (0.50) | — | |
| SCHEMBL11138911 | 1.00 | CA1 (0.50) | — | |
| SCHEMBL9697682 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL11166517 | 0.71 | CA4 (0.50) | — | |
| SCHEMBL5877920 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL11063557 | 0.71 | CA4 (0.50) | — | |
| SCHEMBL516669 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | disclosed |
| EP-4702044-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS WITH BIO-DISTRIBUTION MODIFIER | 3B Pharmaceuticals GmbH (DE) | 2026-03-04 | — | — | EP | disclosed |
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-11-06 | — | — | US | disclosed |
| EP-4583917-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025109003-A1 | P-CADHERIN LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-05-30 | — | — | WO | disclosed |
| CN-119923279-A | Prostate Specific Membrane Antigen (PSMA) ligands and uses thereof | 3B制药有限公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2024223742-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS WITH BIO-DISTRIBUTION MODIFIER | 3B PHARMACEUTICALS GMBH (DE) | 2024-10-31 | — | — | WO | disclosed |
| EP-4448544-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2024-10-23 | — | — | EP | disclosed |
| US-20240335569-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3 B Pharmaceuticals GmbH (DE) | 2024-10-10 | — | — | US | disclosed |
| CN-109994638-B | Organic light emitting device and electronic device | 三星显示有限公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-4373529-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2024-05-29 | — | — | EP | disclosed |
| WO-2024052431-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023111350-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023002045-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-01-26 | — | — | WO | disclosed |
| EP-4091077-A1 | METHODS SYSTEMS AND COMPUTER PROGRAM PRODUCTS FOR SPECIFICATION DATA MANAGEMENT AND GENERATION OF ELECTRONIC BILL OF MATERIAL | Specright, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-11361359-B2 | Methods systems and computer program products for specification data management and generation of electronic bill of material | SPECRIGHT, INC. (US) | 2022-06-14 | — | — | US | disclosed |